Free Trial
NASDAQ:KMDA

Kamada (KMDA) Stock Price, News & Analysis

Kamada logo
$6.61 -0.14 (-2.07%)
Closing price 03/31/2025 04:00 PM Eastern
Extended Trading
$6.61 0.00 (0.00%)
As of 03/31/2025 06:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Kamada Stock (NASDAQ:KMDA)

Key Stats

Today's Range
$6.44
$6.65
50-Day Range
$6.61
$8.33
52-Week Range
$4.74
$9.16
Volume
121,890 shs
Average Volume
79,358 shs
Market Capitalization
$379.94 million
P/E Ratio
23.61
Dividend Yield
N/A
Price Target
$14.67
Consensus Rating
Buy

Company Overview

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite. The company also distributes imported drug products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX for hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.

Remove Ads

Kamada Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
77th Percentile Overall Score

KMDA MarketRank™: 

Kamada scored higher than 77% of companies evaluated by MarketBeat, and ranked 230th out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Kamada has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Kamada has only been the subject of 2 research reports in the past 90 days.

  • Read more about Kamada's stock forecast and price target.
  • Earnings Growth

    Earnings for Kamada are expected to grow by 39.13% in the coming year, from $0.23 to $0.32 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Kamada is 23.61, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 22.47.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Kamada is 23.61, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 23.64.

  • Price to Earnings Growth Ratio

    Kamada has a PEG Ratio of 0.97. PEG Ratios around 1 indicate that a company is correctly valued.

  • Price to Book Value per Share Ratio

    Kamada has a P/B Ratio of 1.56. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Kamada's valuation and earnings.
  • Percentage of Shares Shorted

    0.18% of the float of Kamada has been sold short.
  • Short Interest Ratio / Days to Cover

    Kamada has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Kamada has recently increased by 61.82%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Kamada does not currently pay a dividend.

  • Dividend Growth

    Kamada does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.18% of the float of Kamada has been sold short.
  • Short Interest Ratio / Days to Cover

    Kamada has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Kamada has recently increased by 61.82%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Kamada has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.80 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 5 news articles for Kamada this week, compared to 2 articles on an average week.
  • MarketBeat Follows

    5 people have added Kamada to their MarketBeat watchlist in the last 30 days. This is an increase of 67% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Kamada insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    36.10% of the stock of Kamada is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 20.38% of the stock of Kamada is held by institutions.

  • Read more about Kamada's insider trading history.
Receive KMDA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kamada and its competitors with MarketBeat's FREE daily newsletter.

KMDA Stock News Headlines

Kamada (NASDAQ:KMDA) Stock Rating Lowered by StockNews.com
Revealed: The Chip Stock Redefining AI as We Know It
In this urgent presentation, Wall Street's so-called "AI Oracle" unveils the name of a small American tech firm poised to disrupt the $1 trillion semiconductor industry. He's the same expert who spotted Apple before the iPhone, Amazon before it dominated retail, and Google before it became a verb. Back then, Wall Street shrugged. They're doing it again—ignoring his latest prediction. But according to his research, what we've seen from AI so far is just the beginning. The real boom is still ahead.
Kamada (NASDAQ:KMDA) Coverage Initiated at Benchmark
Kamada initiated with a Buy at Benchmark
Kamada opens third plasma collection center in San Antonio, Texas
See More Headlines

KMDA Stock Analysis - Frequently Asked Questions

Kamada's stock was trading at $6.09 on January 1st, 2025. Since then, KMDA shares have increased by 8.5% and is now trading at $6.61.
View the best growth stocks for 2025 here
.

Kamada Ltd. (NASDAQ:KMDA) issued its earnings results on Wednesday, August, 16th. The biotechnology company reported $0.04 earnings per share for the quarter, beating analysts' consensus estimates of $0.02 by $0.02. The biotechnology company earned $37.44 million during the quarter, compared to the consensus estimate of $34.18 million. Kamada had a net margin of 9.92% and a trailing twelve-month return on equity of 6.30%.

Shares of KMDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Kamada investors own include Xtrackers California Municipal Bond ETF (CA), BlackRock (BLK), Endologix (ELGX), NVIDIA (NVDA), Chipotle Mexican Grill (CMG), ASML (ASML) and Oracle (ORCL).

Company Calendar

Last Earnings
8/16/2023
Record date for 4/7 Dividend
3/17/2025
Ex-Dividend for 4/7 Dividend
3/17/2025
Today
4/01/2025
Dividend Payable
4/07/2025
Next Earnings (Estimated)
5/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:KMDA
Employees
360
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$14.67
High Stock Price Target
$18.00
Low Stock Price Target
$11.00
Potential Upside/Downside
+121.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Trailing P/E Ratio
23.61
Forward P/E Ratio
28.74
P/E Growth
0.97
Net Income
$8.28 million
Pretax Margin
10.04%

Debt

Sales & Book Value

Annual Sales
$160.95 million
Cash Flow
$0.37 per share
Price / Cash Flow
17.90
Book Value
$4.25 per share
Price / Book
1.56

Miscellaneous

Free Float
36,730,000
Market Cap
$379.94 million
Optionable
Optionable
Beta
0.97
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?

Get This Free Report

This page (NASDAQ:KMDA) was last updated on 4/1/2025 by MarketBeat.com Staff
From Our Partners